199 related articles for article (PubMed ID: 2813496)
1. Effects of 5-lipoxygenase inhibition on cardiac anaphylaxis in isolated guinea pig hearts.
Jolly SR; Travis J; Van Inwegen RG
Pharmacology; 1989; 38(6):352-62. PubMed ID: 2813496
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of 5-lipoxygenase by RG 6866.
Carnathan GW; Sweeney DM; Travis JJ; Gordon RJ; Sutherland CA; Jariwala N; Clearfield M; O'Rourke S; Huang FC; Van Inwegen RG
Agents Actions; 1989 Nov; 28(3-4):204-11. PubMed ID: 2596372
[TBL] [Abstract][Full Text] [Related]
3. Modulation of coronary flow rate and cardiac contractility by the divalent cation ionophore A23187 and inhibitors of the cyclooxygenase and 5-lipoxygenase pathways: development of heterogeneous patterns of myocardial ischemia.
Björnsson OG; Kobayashi K; Williamson JR
Naunyn Schmiedebergs Arch Pharmacol; 1988 Feb; 337(2):191-202. PubMed ID: 3130582
[TBL] [Abstract][Full Text] [Related]
4. Effects of exogenous prostaglandins on the release of leukotriene C4-like immunoreactivity and on coronary flow in indomethacin-treated anaphylactic guinea-pig hearts.
Aehringhaus U; Dembinska-Kiéc A; Peskar BA
Naunyn Schmiedebergs Arch Pharmacol; 1984 Jul; 326(4):368-74. PubMed ID: 6384796
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: effects on bronchial anaphylaxis in anaesthetized guinea-pigs.
Payne AN; Garland LG; Lees IW; Salmon JA
Br J Pharmacol; 1988 Jun; 94(2):540-6. PubMed ID: 3395791
[TBL] [Abstract][Full Text] [Related]
6. Effect of neuropeptide Y on isolated rat hearts.
Jolly SR; Ordoukhani A; Movahed A
Pharmacology; 1991; 43(3):121-7. PubMed ID: 1775516
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of leukotriene release in anaphylactic guinea-pig hearts by a 5-lipoxygenase inhibitor, CGS 8515.
Yaacob HB; Piper PJ
Br J Pharmacol; 1988 Dec; 95(4):1322-8. PubMed ID: 3146401
[TBL] [Abstract][Full Text] [Related]
8. Effect of exogenous 5,8,11,14,17-eicosapentaenoic acid on cardiac anaphylaxis.
Juan H; Peskar BA; Simmet T
Br J Pharmacol; 1987 Feb; 90(2):315-25. PubMed ID: 2881590
[TBL] [Abstract][Full Text] [Related]
9. Effects of leukotrienes C4 and D4 on guinea-pig heart and the participation of SRS-A in the manifestations of guinea-pig cardiac anaphylaxis.
Ezeamuzie IC; Assem ES
Agents Actions; 1983 Apr; 13(2-3):182-7. PubMed ID: 6869121
[TBL] [Abstract][Full Text] [Related]
10. Effect of inhibition of synthesis and receptor antagonism of SRS-A in cardiac anaphylaxis.
Aehringhaus U; Peskar BA; Wittenberg HR; Wölbling RH
Br J Pharmacol; 1983 Sep; 80(1):73-80. PubMed ID: 6689134
[TBL] [Abstract][Full Text] [Related]
11. Release of calcitonin gene-related peptide in cardiac anaphylaxis.
Schuligoi R; Amann R; Donnerer J; Peskar BA
Naunyn Schmiedebergs Arch Pharmacol; 1997 Feb; 355(2):224-9. PubMed ID: 9050016
[TBL] [Abstract][Full Text] [Related]
12. Effects of a 5-lipoxygenase inhibitor, REV-5901, on leukotriene and histamine release from human lung tissue in-vitro.
Tennant CM; Seale JP; Temple DM
J Pharm Pharmacol; 1987 Apr; 39(4):309-11. PubMed ID: 2438401
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of leukotriene receptors and administration of a 5-lipoxygenase inhibitor do not affect hypoxic vasoconstriction.
Thomas HM; Sourour MS; Lopez D; Foster SH
Lung; 1989; 167(3):187-98. PubMed ID: 2567790
[TBL] [Abstract][Full Text] [Related]
14. Myocardial salvage induced by REV-5901: an inhibitor and antagonist of the leukotrienes.
Mullane K; Hatala MA; Kraemer R; Sessa W; Westlin W
J Cardiovasc Pharmacol; 1987 Oct; 10(4):398-406. PubMed ID: 2444792
[TBL] [Abstract][Full Text] [Related]
15. 2,3,5-Trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone (AA861), a selective inhibitor of the 5-lipoxygenase reaction and the biosynthesis of slow-reacting substance of anaphylaxis.
Yoshimoto T; Yokoyama C; Ochi K; Yamamoto S; Maki Y; Ashida Y; Terao S; Shiraishi M
Biochim Biophys Acta; 1982 Nov; 713(2):470-3. PubMed ID: 6817808
[TBL] [Abstract][Full Text] [Related]
16. Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo models.
Ku EC; Raychaudhuri A; Ghai G; Kimble EF; Lee WH; Colombo C; Dotson R; Oglesby TD; Wasley JW
Biochim Biophys Acta; 1988 Apr; 959(3):332-42. PubMed ID: 2833314
[TBL] [Abstract][Full Text] [Related]
17. Wy-45,911: a novel leukotriene antagonist with lipoxygenase inhibitory activity.
Musser JH; Kubrak DM; Chang J; Lewis AJ
Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():536-9. PubMed ID: 2959109
[No Abstract] [Full Text] [Related]
18. The effects of a novel series of selective inhibitors of arachidonate 5-lipoxygenase on anaphylactic and inflammatory responses.
Bhattacherjee P; Boughton-Smith NK; Follenfant RL; Garland LG; Higgs GA; Hodson HF; Islip PJ; Jackson WP; Moncada S; Payne AN
Ann N Y Acad Sci; 1988; 524():307-20. PubMed ID: 2837965
[TBL] [Abstract][Full Text] [Related]
19. Interaction between leukotriene D4 and adenosine or iloprost in the isolated working guinea-pig heart: prevention of the leukotriene D4 effect.
Björnsson OG; Kobayashi K; Williamson JR
Eur J Clin Invest; 1987 Apr; 17(2):146-55. PubMed ID: 2438141
[TBL] [Abstract][Full Text] [Related]
20. N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
Musser JH; Kreft AF; Bender RH; Kubrak DM; Carlson RP; Chang J; Hand JM
J Med Chem; 1989 Jun; 32(6):1176-83. PubMed ID: 2498516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
